Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections

被引:22
作者
Nenoff, P
Haustein, UF
Hittel, N
机构
[1] Lab Med Mikrobiol, DE-04579 Molbis, Germany
[2] Univ Leipzig, Dept Dermatol, Leipzig, Germany
[3] Otsuka Pharmaceut Co Ltd, Frankfurt, Germany
关键词
coagulase-negative staphylococci; fluoroquinolone; minimum inhibitory concentration; nadifloxacin; propionibacteria; Staphylococcus aureus; streptococci;
D O I
10.1159/000081032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Methods: The in vitro activity of nadifloxacin (OPC-7251), a novel topical fluoroquinolone, was assessed and compared with those of ofloxacin, oxacillin, flucloxacillin, cefotiam, erythromycin, clindamycin, and gentamicin against 144 Gram-positive bacteria: 28 Staphylococcus aureus, 10 Streptococcus spp., 68 coagulase-negative staphylococci (CNS), 36 Propionibacterium acnes, and 2 Propionibacterium granulosum strains. All strains originated from bacterial-infected skin disease and were isolated from patients with impetigo, secondary infected wounds, folliculitis and sycosis vulgaris, and impetiginized dermatitis. In vitro susceptibility of all clinical isolates was tested by agar dilution procedure and minimum inhibitory concentrations (MICs) were determined. Results: Nadifloxacin was active against all aerobic and anaerobic isolates. MIC90 ( MIC at which 90% of the isolates are inhibited) was 0.1 mug/ml for S. aureus, 0.78 mug/ml for both Streptococcus spp. and CNS, and 0.39 mug/ml for Propionibacterium spp. On the other hand, resistant strains with MICs exceeding 12.5 mug/ml were found in tests with the other antibiotics. For both CNS and Propionibacterium acnes, MIC90 values uses greater than or equal to 100 mug/ml were demonstrated for erythromycin. Ofloxacin, cefotiam, erythromycin, clindamycin and gentamicin exhibited MIC90 values less than or equal to1 mug/ml for some bacterial species tested. Both oxacillin and flucloxacillin were active against all investigated bacterial species with MIC90 values less than or equal to1 mug/ml. Conclusion: In summary, nadifloxacin, a topical fluoroquinolone, was found to be highly active against aerobic and anaerobic bacteria isolated from patients with infected skin disease, and seems to be a new alternative for topical antibiotic treatment in bacterial skin infections. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:196 / 201
页数:6
相关论文
共 39 条
[1]  
Bojar R A, 1995, Drugs, V49 Suppl 2, P164
[2]   STRUCTURE-ACTIVITY-RELATIONSHIPS OF THE FLUOROQUINOLONES [J].
CHU, DTW ;
FERNANDES, PB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (02) :131-135
[3]  
Crumplin G C, 1988, Rev Infect Dis, V10 Suppl 1, pS2
[4]   NEW STRUCTURE-ACTIVITY-RELATIONSHIPS OF THE QUINOLONE ANTIBACTERIALS USING THE TARGET ENZYME - THE DEVELOPMENT AND APPLICATION OF A DNA GYRASE ASSAY [J].
DOMAGALA, JM ;
HANNA, LD ;
HEIFETZ, CL ;
HUTT, MP ;
MICH, TF ;
SANCHEZ, JP ;
SOLOMON, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (03) :394-404
[5]   Comparative in vitro activity of cider and newer fluoroquinolones against respiratory tract pathogens [J].
Esposito, S ;
Noviello, S ;
Ianniello, F .
CHEMOTHERAPY, 2000, 46 (05) :309-314
[6]   Topical drug treatment in acne [J].
Gollnick, H ;
Schramm, M .
DERMATOLOGY, 1998, 196 (01) :119-125
[7]  
GOLLNICK HPM, 1994, EUR J DERMATOL, V4, P210
[8]   Topical quinolone nadifloxacin (OPC-7251) in bacterial skin disease: Clinical evaluation in a multicenter open trial and in vitro antimicrobiological susceptibility testing [J].
Haustein, UF ;
Nenoff, P ;
Hittel, N ;
Klovekorn, W ;
Krieg, T ;
Plewig, G ;
PoncePoschl, E ;
Ruzicka, T ;
Tannenberg, H ;
Thummes, R ;
Wolff, H .
JOURNAL OF DERMATOLOGICAL TREATMENT, 1997, 8 (02) :87-92
[9]  
HAUSTEIN UF, 1996, SKIN PHARMACOL, V9, P151
[10]  
Iwahara K, 1999, EUR J DERMATOL, V9, P276